![]() Research continues into using JAK inhibitors to treat UC. The 2021 paper lists tofacitinib and filgotinib as other recent JAK inhibitors for UC. In 2022, the Food and Drug Administration (FDA) approved upadacitinib as a treatment for UC. It also caused signs of remission inside the colon, which doctors could measure using an endoscopy. At higher dosages, this medication induced remission in nearly one-third of study participants. Since rheumatoid arthritis is also an inflammatory condition, scientists have begun to research whether this drug could positively impact UC.Ī 2021 paper on the scientific research notes several studies in which upadacitinib performed better than a placebo. Upadacitinib has shown promise in treating rheumatoid arthritis. JAK is an enzyme, and JAK inhibitors reduce its activity. A 2023 review states that upadacitinib is a new Janus kinase (JAK) inhibitor.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |